RT Journal Article
SR Electronic
T1 Epidemiological drivers of transmissibility and severity of SARS-CoV-2 in England
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.10.23285516
DO 10.1101/2023.02.10.23285516
A1 Perez-Guzman, Pablo N
A1 Knock, Edward
A1 Imai, Natsuko
A1 Rawson, Thomas
A1 Elmaci, Yasin
A1 Alcada, Joana
A1 Whittles, Lilith K
A1 Kanapram, Divya Thekke
A1 Sonabend, Raphael
A1 Gaythorpe, Katy AM
A1 Hinsley, Wes
A1 FitzJohn, Richard G
A1 Volz, Erik
A1 Verity, Robert
A1 Ferguson, Neil M
A1 Cori, Anne
A1 Baguelin, Marc
YR 2023
UL http://medrxiv.org/content/early/2023/05/22/2023.02.10.23285516.abstract
AB As the SARS-CoV-2 pandemic progressed, distinct variants emerged and dominated in England. These variants, Wildtype, Alpha, Delta, and Omicron were characterized by variations in transmissibility and severity. We used a robust mathematical model and Bayesian inference framework to analyse epidemiological surveillance data from England. We quantified the impact of non-pharmaceutical interventions (NPIs), therapeutics, and vaccination on virus transmission and severity. Each successive variant had a higher intrinsic transmissibility. Omicron (BA.1) had the highest basic reproduction number at 8.3 (95% credible interval (CrI) 7.7-8.8). Varying levels of NPIs were crucial in controlling virus transmission until population immunity accumulated. Immune escape properties of Omicron decreased effective levels of immunity in the population by a third. Furthermore, in contrast to previous studies, we found Alpha had the highest basic infection fatality ratio (2.9%, 95% CrI 2.7-3.2), followed by Delta (2.2%, 95% CrI 2.0-2.4), Wildtype (1.2%, 95% CrI 1.1-1.2), and Omicron (0.7%, 95% CrI 0.6-0.8). Our findings highlight the importance of continued surveillance. Long-term strategies for monitoring and maintaining effective immunity against SARS-CoV-2 are critical to inform the role of NPIs to effectively manage future variants with potentially higher intrinsic transmissibility and severe outcomes.Competing Interest StatementPPG has consulted for Pfizer. AC has received payment from Pfizer for teaching of mathematical modelling of infectious diseases. RS and NI are currently employed by the Wellcome Trust, however the Wellcome Trust had no role in the study design, data collection, data analysis, data interpretation or writing of the manuscript. KAMG has received honoraria from Wellcome Genome Campus for lectures and salary support from the Bill & Melinda Gates Foundation and Gavi, the Vaccine Alliance, through Imperial College London for work outside this study. LKW has received consultancy payments from the Wellcome Trust. All other authors declare no competing interests. All other authors declare no competing interests. For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.Funding StatementThis work was supported jointly by the Wellcome Trust and the Department for International Development (DFID; 221350)]. This work was supported by the Medical Research Council (MRC) Centre for Global Infectious Disease Analysis (grant number MR/R015600/1); this award is jointly funded by the MRC and Foreign, Commonwealth and Development Office (FCDO) under the MRC/FCDO Concordat agreement, and is also part of the European and Developing Countries Clinical Trials Partnership programme supported by the EU. This work was also supported by the National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in Modelling and Health Economics, which is a partnership between the UK Health Security Agency (UKHSA), Imperial College London, and the London School of Hygiene & Tropical Medicine (grant code NIHR200908). LKW is funded by the Wellcome Trust (grant number 218669/Z/19/Z). The views expressed are those of the authors and not necessarily those of the UK Department of Health and Social Care (DHSC), FCDO, EU, MRC, NIHR, UKHSA, or Wellcome Trust.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics permission was sought for the study through the standard ethical review processes of Imperial College London (London, UK), and was approved by the university's research governance and integrity team (Imperial College Research Ethics Committee reference 21IC6945). Patient consent was not required as the research team accessed fully anonymised data only, which were collected as part of routine public health surveillance activities by the UK Government.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data necessary to reproduce the analysis in the present study are available online at https://github.com/mrc-ide/sarscov2-severity-england. https://github.com/mrc-ide/sarscov2-severity-england